Diabetic Nephropathy and COVID-19: The Potential Role of Immune Actors
Abstract
:1. Introduction
- Search Terms: Diabetes Nephropathy AND COVID19 (1);
- Search Engines: Pubmed OR Scopus OR Google Scholar OR ClinicalTrials.gov (2);
- Search Combination: (1) AND (2);
2. Discussion
2.1. The Well-Known ACE Role and Its Controversial Involvement
2.2. The Less Well-Known NRP-1 Role and Its Remarkable Potential
2.3. Other Suggested Underlying Actors
2.3.1. Mitochondrial Glutathione
2.3.2. Vitamin D
2.3.3. Dipeptidyl Peptidase-4
3. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Soliman, A.; Nair, A.P.; Al Masalamani, M.S.; De Sanctis, V.; Abu Khattab, M.A.; Alsaud, A.E.; Sasi, S.; Ali, E.A.; Hassan, O.A.; Iqbal, F.M.; et al. Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study. Acta Bio-Med. 2020, 91, e2020010. [Google Scholar] [PubMed]
- Wu, Z.-H.; Tang, Y.; Cheng, Q. Diabetes increases the mortality of patients with COVID-19: A meta-analysis. Acta Diabetol. 2020, 58, 139–144. [Google Scholar] [CrossRef] [PubMed]
- Varikasuvu, S.R.; Dutt, N.; Thangappazham, B.; Varshney, S. Diabetes and COVID-19: A pooled analysis related to disease severity and mortality. Prim. Care Diabetes 2021, 15, 24–27. [Google Scholar] [CrossRef] [PubMed]
- Rivero, J.; Merino-López, M.; Olmedo, R.; Garrido-Roldan, R.; Moguel, B.; Rojas, G.; Chavez-Morales, A.; Alvarez-Maldonado, P.; Duarte-Molina, P.; Castano-Guerra, R.; et al. Association between Postmortem Kidney Biopsy Findings and Acute Kidney Injury from Patients with SARS-CoV-2 (COVID-19). Clin. J. Am. Soc. Nephrol. 2021, 16, 685–693. [Google Scholar] [CrossRef]
- Corcillo, A.; Cohen, S.; Game, D.; Karalliedde, J. High prevalence of Afro-Caribbean ethnicity and hypoglycaemia in patients with diabetes and end stage renal disease hospitalized with COVID-19. Nephrology 2020, 26, 252–254. [Google Scholar] [CrossRef] [PubMed]
- Leon-Abarca, J.A.; Memon, R.S.; Rehan, B.; Iftikhar, M.; Chatterjee, A. The impact of COVID-19 in diabetic kidney disease and chronic kidney disease: A population-based study. Acta Bio-Med. 2020, 91, e2020161. [Google Scholar] [PubMed]
- Alnomasy, S.F. Virus-receptor interactions of SARS-CoV-2 spike receptor-binding domain and human neuropilin-1 b1 domain. Saudi J. Biol. Sci. 2021, 28, 3926–3928. [Google Scholar] [CrossRef]
- Gadanec, L.K.; McSweeney, K.R.; Qaradakhi, T.; Ali, B.; Zulli, A.; Apostolopoulos, V. Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells? Int. J. Mol. Sci. 2021, 22, 992. [Google Scholar] [CrossRef] [PubMed]
- Stafford, E.G.; Riviere, J.E.; Xu, X.; Kawakami, J.; Wyckoff, G.J.; Jaberi-Douraki, M. Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality. J. Am. Pharm. Assoc. 2020, 60, e145–e152. [Google Scholar] [CrossRef]
- Sarangarajan, R.; Winn, R.; Kiebish, M.A.; Bountra, C.; Granger, E.; Narain, N.R. Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers. J. Racial Ethn. Health Disparities 2020, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Heyman, S.; Walther, T.; Abassi, Z. Angiotensin-(1–7)—A Potential Remedy for AKI: Insights Derived from the COVID-19 Pandemic. J. Clin. Med. 2021, 10, 1200. [Google Scholar] [CrossRef] [PubMed]
- Ren, X.; Wang, S.; Chen, X.; Wei, X.; Li, G.; Ren, S.; Zhang, T.; Zhang, X.; Lu, Z.; You, Z.; et al. Multiple Expression Assessments of ACE2 and TMPRSS2 SARS-CoV-2 Entry Molecules in the Urinary Tract and Their Associations with Clinical Manifestations of COVID-19. Infect. Drug Resist. 2020, 13, 3977–3990. [Google Scholar] [CrossRef]
- Menon, R.; Otto, E.A.; Sealfon, R.; Nair, V.; Wong, A.K.; Theesfeld, C.L.; Chen, X.; Wang, Y.; Boppana, A.S.; Luo, J.; et al. SARS-CoV-2 receptor networks in diabetic and COVID-19-associated kidney disease. Kidney Int. 2020, 98, 1502–1518. [Google Scholar] [CrossRef] [PubMed]
- Menon, R.; Otto, E.A.; Sealfon, R.; Nair, V.; Wong, A.K.; Theesfeld, C.L.; Chen, X.; Wang, Y.; Schaub, J.A.; Berthier, C.C.; et al. SARS-CoV-2 receptor networks in diabetic kidney disease, BK-Virus nephropathy and COVID-19 associated acute kidney injury. medRxiv 2020. [Google Scholar] [CrossRef]
- Gilbert, R.E.; Caldwell, L.; Misra, P.S.; Chan, K.; Burns, K.D.; Wrana, J.L.; Yuen, D. Overexpression of the Severe Acute Respiratory Syndrome Coronavirus-2 Receptor, Angiotensin-Converting Enzyme 2, in Diabetic Kidney Disease: Implications for Kidney Injury in Novel Coronavirus Disease 2019. Can. J. Diabetes 2021, 45, 162–166. [Google Scholar] [CrossRef] [PubMed]
- Triposkiadis, F.; Starling, R.C.; Xanthopoulos, A.; Butler, J.; Boudoulas, H. Renin-angiotensin-system inhibition in the context of corona virus disease-19: Experimental evidence, observational studies, and clinical implications. Heart Fail. Rev. 2020, 26, 381–389. [Google Scholar] [CrossRef] [PubMed]
- Bondeva, T.; Wolf, G. Role of Neuropilin-1 in Diabetic Nephropathy. J. Clin. Med. 2015, 4, 1293–1311. [Google Scholar] [CrossRef] [Green Version]
- Perez-Miller, S.; Patek, M.; Moutal, A.; Duran, P.; Cabel, C.R.; Thorne, C.A.; Campos, S.K.; Khanna, R. Novel Compounds Targeting Neuropilin Receptor 1 with Potential to Interfere with SARS-CoV-2 Virus Entry. ACS Chem. Neurosci. 2021, 12, 1299–1312. [Google Scholar] [CrossRef]
- Mayi, B.S.; Leibowitz, J.A.; Woods, A.T.; Ammon, K.A.; Liu, A.E.; Raja, A. The role of Neuropilin-1 in COVID-19. PLoS Pathog. 2021, 17, e1009153. [Google Scholar] [CrossRef]
- Vique-Sánchez, J.L. Potential inhibitors interacting in Neuropilin-1 to develop an adjuvant drug against COVID-19, by molecular docking. Bioorganic Med. Chem. 2021, 33, 116040. [Google Scholar] [CrossRef]
- Jobe, A.; Vijayan, R. Neuropilins: C-end rule peptides and their association with nociception and COVID-19. Comput. Struct. Biotechnol. J. 2021, 19, 1889–1895. [Google Scholar] [CrossRef]
- Moutal, A.; Martin, L.F.; Boinon, L.; Gomez, K.; Ran, D.; Zhou, Y.; Stratton, H.J.; Cai, S.; Luo, S.; Gonzalez, K.B.; et al. SARS-CoV-2 spike protein co-opts VEGF-A/neuropilin-1 receptor signaling to induce analgesia. Pain 2021, 162, 243–252. [Google Scholar] [CrossRef]
- Li, Z.-L.; Buck, M. Neuropilin-1 Assists SARS-CoV-2 Infection by Stimulating the Separation of Spike Protein Domains S1 and S2. bioRxiv 2021. [Google Scholar] [CrossRef]
- Ord, M.; Faustova, I.; Loog, M. The sequence at Spike S1/S2 site enables cleavage by furin and phospho-regulation in SARS-CoV2 but not in SARS-CoV1 or MERS-CoV. Sci. Rep. 2020, 10, 16944. [Google Scholar] [CrossRef]
- Bondeva, T.; Rüster, C.; Franke, S.; Hammerschmid, E.; Klagsbrun, M.; Cohen, C.D.; Wolf, G. Advanced glycation end-products suppress neuropilin-1 expression in podocytes. Kidney Int. 2009, 75, 605–616. [Google Scholar] [CrossRef] [Green Version]
- Bondeva, T.; Wojciech, S.; Wolf, G. Advanced glycation end products inhibit adhesion ability of differentiated podocytes in a neuropilin-1-dependent manner. Am. J. Physiol. Physiol. 2011, 301, F852–F870. [Google Scholar] [CrossRef] [PubMed]
- Loeffler, I.; Rüster, C.; Franke, S.; Liebisch, M.; Wolf, G. Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db/db mouse. Am. J. Physiol. Physiol. 2013, 305, F911–F918. [Google Scholar] [CrossRef] [Green Version]
- Bondeva, T.; Wolf, G. Advanced Glycation End Products Suppress Neuropilin-1 Expression in Podocytes by a Reduction in Sp1-Dependent Transcriptional Activity. Am. J. Nephrol. 2009, 30, 336–345. [Google Scholar] [CrossRef] [PubMed]
- Cantuti-Castelvetri, L.; Ojha, R.; Pedro, L.D.; Djannatian, M.; Franz, J.; Kuivanen, S.; Van der Meer, F.; Kallio, K.; Kaya, T.; Anastasina, M.; et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 2020, 370, 856–860. [Google Scholar] [CrossRef] [PubMed]
- Marí, M.; De Gregorio, E.; De Dios, C.; Roca-Agujetas, V.; Cucarull, B.; Tutusaus, A.; Morales, A.; Colell, A. Mitochondrial Glutathione: Recent Insights and Role in Disease. Antioxidants 2020, 9, 909. [Google Scholar] [CrossRef] [PubMed]
- Naik, E.; Dixit, V.M. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. J. Exp. Med. 2011, 208, 417–420. [Google Scholar] [CrossRef] [PubMed]
- Khanfar, A.; Al Qaroot, B. Could glutathione depletion be the Trojan horse of COVID-19 mortality? Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 12500–12509. [Google Scholar]
- Guloyan, V.; Oganesian, B.; Baghdasaryan, N.; Yeh, C.; Singh, M.; Guilford, F.; Ting, Y.-S.; Venketaraman, V. Glutathione Supplementation as an Adjunctive Therapy in COVID-19. Antioxidants 2020, 9, 914. [Google Scholar] [CrossRef]
- Silvagno, F.; Vernone, A.; Pescarmona, G.P. The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19. Antioxidants 2020, 9, 624. [Google Scholar] [CrossRef] [PubMed]
- Lash, L.H. Mitochondrial Glutathione in Diabetic Nephropathy. J. Clin. Med. 2015, 4, 1428–1447. [Google Scholar] [CrossRef] [Green Version]
- Beisswenger, P.J.; Drummond, K.S.; Nelson, R.G.; Howell, S.K.; Szwergold, B.S.; Mauer, M. Susceptibility to Diabetic Nephropathy Is Related to Dicarbonyl and Oxidative Stress. Diabetes 2005, 54, 3274–3281. [Google Scholar] [CrossRef] [PubMed]
- Ueno, Y.; Kizaki, M.; Nakagiri, R.; Kamiya, T.; Sumi, H.; Osawa, T. Dietary Glutathione Protects Rats from Diabetic Nephropathy and Neuropathy. J. Nutr. 2002, 132, 897–900. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bilezikian, J.P.; Bikle, D.; Hewison, M.; Lazaretti-Castro, M.; Formenti, A.M.; Gupta, A.; Madhavan, M.V.; Nair, N.; Babalyan, V.; Hutchings, N.; et al. Mechanisms in Endocrinology: Vitamin D and COVID-19. Eur. J. Endocrinol. 2020, 183, R133–R147. [Google Scholar] [CrossRef]
- Galuška, D.; Pácal, L.; Kaňková, K. Pathophysiological Implication of Vitamin D in Diabetic Kidney Disease. Kidney Blood Press Res. 2021, 46, 152–161. [Google Scholar] [CrossRef] [PubMed]
- Mitchell, F. Vitamin-D and COVID-19: Do deficient risk a poorer outcome? Lancet Diabetes Endocrinol. 2020, 8, 570. [Google Scholar] [CrossRef]
- Mohan, M.; Cherian, J.J.; Sharma, A. Exploring links between vitamin D deficiency and COVID-19. PLoS Pathog. 2020, 16, e1008874. [Google Scholar] [CrossRef]
- Husemoen, L.L.N.; Thuesen, B.; Fenger, M.; Jørgensen, T.; Glümer, C.; Svensson, J.; Ovesen, L.; Witte, D.R.; Linneberg, A. Serum 25(OH)D and Type 2 Diabetes Association in a General Population: A prospective study. Diabetes Care 2012, 35, 1695–1700. [Google Scholar] [CrossRef] [Green Version]
- Derakhshanian, H.; Shab-Bidar, S.; Speakman, J.R.; Nadimi, H.; Djafarian, K. Vitamin D and diabetic nephropathy: A systematic review and meta-analysis. Nutrition 2015, 31, 1189–1194. [Google Scholar] [CrossRef]
- Lei, M.; Liu, Z.; Guo, J. The Emerging Role of Vitamin D and Vitamin D Receptor in Diabetic Nephropathy. BioMed Res. Int. 2020, 2020, 1–8. [Google Scholar] [CrossRef]
- Hu, X.; Liu, W.; Yan, Y.; Liu, H.; Huang, Q.; Xiao, Y.; Gong, Z.; Du, J. Vitamin D protects against diabetic nephropathy: Evidence-based effectiveness and mechanism. Eur. J. Pharmacol. 2019, 845, 91–98. [Google Scholar] [CrossRef] [PubMed]
- Derakhshanian, H.; Djazayery, A.; Javanbakht, M.H.; Eshraghian, M.R.; Mirshafiey, A.; Zarei, M.; Alvandi, E.; Djalali, E.; Djalali, M. The Effect of Vitamin D on Cellular Pathways of Diabetic Nephropathy. Rep. Biochem. Mol. Biol. 2019, 7, 217–222. [Google Scholar]
- Solerte, S.B.; Di Sabatino, A.; Galli, M.; Fiorina, P. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetol. 2020, 57, 779–783. [Google Scholar] [CrossRef]
- Muskiet, M.; Tonneijck, L.; Smits, M.M.; Van Baar, M.J.; Kramer, M.H.H.; Hoorn, E.J.; Joles, J.A.; Van Raalte, D.H. GLP-1 and the kidney: From physiology to pharmacology and outcomes in diabetes. Nat. Rev. Nephrol. 2017, 13, 605–628. [Google Scholar] [CrossRef] [PubMed]
- Danta, C.C. Dipeptidyl Peptidase-4: A Potential Therapeutic Target in Diabetic Kidney Disease with SARS-CoV-2 Infection. ACS Pharmacol. Transl. Sci. 2020, 3, 1020–1022. [Google Scholar] [CrossRef] [PubMed]
- Vankadari, N.; Wilce, J.A. Emerging WuHan (COVID-19) coronavirus: Glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg. Microbes Infect. 2020, 9, 601–604. [Google Scholar] [CrossRef] [PubMed]
- Sharkovska, Y.; Reichetzeder, C.; Alter, M.; Tsuprykov, O.; Bachmann, S.; Secher, T.; Klein, T.; Hocher, B. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. J. Hypertens. 2014, 32, 2211–2223. [Google Scholar] [CrossRef]
- Wada, J.; Makino, H. Innate immunity in diabetes and diabetic nephropathy. Nat. Rev. Nephrol. 2015, 12, 13–26. [Google Scholar] [CrossRef] [PubMed]
- Doupis, J.; Veves, A. DPP4 Inhibitors: A new approach in diabetes treatment. Adv. Ther. 2008, 25, 627–643. [Google Scholar] [CrossRef] [PubMed]
- Mikov, M.; Pavlović, N.; Stanimirov, B.; Đanić, M.; Goločorbin-Kon, S.; Stankov, K.; Al-Salami, H. DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment. Eur. J. Drug Metab. Pharmacokinet. 2020, 45, 1–14. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mourad, D.; Azar, N.S.; Azar, S.T. Diabetic Nephropathy and COVID-19: The Potential Role of Immune Actors. Int. J. Mol. Sci. 2021, 22, 7762. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22157762
Mourad D, Azar NS, Azar ST. Diabetic Nephropathy and COVID-19: The Potential Role of Immune Actors. International Journal of Molecular Sciences. 2021; 22(15):7762. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22157762
Chicago/Turabian StyleMourad, Diane, Nadim S. Azar, and Sami T. Azar. 2021. "Diabetic Nephropathy and COVID-19: The Potential Role of Immune Actors" International Journal of Molecular Sciences 22, no. 15: 7762. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22157762